Ultragenyx Pharmaceutical CEO Emil Kakkis' 2019 pay jumps 36% to $6.6M
Ultragenyx Pharmaceutical reports 2019 executive compensation
By ExecPay News
Published: April 29, 2020
Ultragenyx Pharmaceutical reported fiscal year 2019 executive compensation information on April 29, 2020.
In 2019, five executives at Ultragenyx Pharmaceutical received on average a compensation package of $3.5M, a 10% increase compared to previous year.
Average pay of disclosed executives at Ultragenyx Pharmaceutical
Emil D. Kakkis, Chief Executive Officer, received $6.6M in total, which increased by 36% compared to 2018. 41% of Kakkis' compensation, or $2.7M, was in stock awards. Kakkis also received $480K in non-equity incentive plan, $2.7M in option awards, $714K in salary, as well as $40K in other compensation.
John R. Pinion II, Chief Quality Officer and Executive Vice President, Translational Sciences, received a compensation package of $3.4M, which increased by 111% compared to previous year. 52% of the compensation package, or $1.8M, was in stock awards.
Shalini Sharp, Chief Financial Officer, earned $2.6M in 2019, a 25% increase compared to previous year.
Camille L. Bedrosian, Chief Medical Officer, received $2.5M in 2019, which decreases by 48% compared to 2018.
Thomas Kassberg, Chief Business Officer and Executive Vice President, earned $2.5M in 2019, a 45% increase compared to previous year.
Related executives
Emil Kakkis
Ultragenyx Pharmaceutical
Chief Executive Officer
Shalini Sharp
Ultragenyx Pharmaceutical
Chief Financial Officer
John Pinion
Ultragenyx Pharmaceutical
Chief Quality Officer and Executive Vice President, Translational Sciences
Camille Bedrosian
Ultragenyx Pharmaceutical
Chief Medical Officer
Thomas Kassberg
Ultragenyx Pharmaceutical
Chief Business Officer and Executive Vice President
You may also like
Source: SEC filing on April 29, 2020.